Tags

Type your tag names separated by a space and hit enter

Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society.
Neurology. 2004 Apr 27; 62(8):1261-73.Neur

Abstract

OBJECTIVE

To assess the evidence demonstrating efficacy, tolerability, and safety of seven new antiepileptic drugs (AEDs) (gabapentin, lamotrigine, topiramate, tiagabine, oxcarbazepine, levetiracetam, and zonisamide) in the treatment of children and adults with refractory partial and generalized epilepsies.

METHODS

A 23-member committee including general neurologists, pediatric neurologists, epileptologists, and doctors in pharmacy evaluated the available evidence based on a structured literature review including MEDLINE, Current Contents, and Cochrane library for relevant articles from 1987 until March 2003.

RESULTS

All of the new AEDs were found to be appropriate for adjunctive treatment of refractory partial seizures in adults. Gabapentin can be effective for the treatment of mixed seizure disorders, and gabapentin, lamotrigine, oxcarbazepine, and topiramate for the treatment of refractory partial seizures in children. Limited evidence suggests that lamotrigine and topiramate are also effective for adjunctive treatment of idiopathic generalized epilepsy in adults and children, as well as treatment of the Lennox Gastaut syndrome.

CONCLUSIONS

The choice of AED depends upon seizure and/or syndrome type, patient age, concomitant medications, AED tolerability, safety, and efficacy. The results of this evidence-based assessment provide guidelines for the prescription of AEDs for patients with refractory epilepsy and identify those seizure types and syndromes where more evidence is necessary.

Authors+Show Affiliations

University of Pennsylvania, Philadelphia, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Guideline
Journal Article
Practice Guideline
Review

Language

eng

PubMed ID

15111660

Citation

French, J A., et al. "Efficacy and Tolerability of the New Antiepileptic Drugs II: Treatment of Refractory Epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society." Neurology, vol. 62, no. 8, 2004, pp. 1261-73.
French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2004;62(8):1261-73.
French, J. A., Kanner, A. M., Bautista, J., Abou-Khalil, B., Browne, T., Harden, C. L., Theodore, W. H., Bazil, C., Stern, J., Schachter, S. C., Bergen, D., Hirtz, D., Montouris, G. D., Nespeca, M., Gidal, B., Marks, W. J., Turk, W. R., Fischer, J. H., Bourgeois, B., ... Glauser, T. A. (2004). Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology, 62(8), 1261-73.
French JA, et al. Efficacy and Tolerability of the New Antiepileptic Drugs II: Treatment of Refractory Epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2004 Apr 27;62(8):1261-73. PubMed PMID: 15111660.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. AU - French,J A, AU - Kanner,A M, AU - Bautista,J, AU - Abou-Khalil,B, AU - Browne,T, AU - Harden,C L, AU - Theodore,W H, AU - Bazil,C, AU - Stern,J, AU - Schachter,S C, AU - Bergen,D, AU - Hirtz,D, AU - Montouris,G D, AU - Nespeca,M, AU - Gidal,B, AU - Marks,W J,Jr AU - Turk,W R, AU - Fischer,J H, AU - Bourgeois,B, AU - Wilner,A, AU - Faught,R E,Jr AU - Sachdeo,R C, AU - Beydoun,A, AU - Glauser,T A, AU - ,, AU - ,, AU - ,, PY - 2004/4/28/pubmed PY - 2004/8/11/medline PY - 2004/4/28/entrez SP - 1261 EP - 73 JF - Neurology JO - Neurology VL - 62 IS - 8 N2 - OBJECTIVE: To assess the evidence demonstrating efficacy, tolerability, and safety of seven new antiepileptic drugs (AEDs) (gabapentin, lamotrigine, topiramate, tiagabine, oxcarbazepine, levetiracetam, and zonisamide) in the treatment of children and adults with refractory partial and generalized epilepsies. METHODS: A 23-member committee including general neurologists, pediatric neurologists, epileptologists, and doctors in pharmacy evaluated the available evidence based on a structured literature review including MEDLINE, Current Contents, and Cochrane library for relevant articles from 1987 until March 2003. RESULTS: All of the new AEDs were found to be appropriate for adjunctive treatment of refractory partial seizures in adults. Gabapentin can be effective for the treatment of mixed seizure disorders, and gabapentin, lamotrigine, oxcarbazepine, and topiramate for the treatment of refractory partial seizures in children. Limited evidence suggests that lamotrigine and topiramate are also effective for adjunctive treatment of idiopathic generalized epilepsy in adults and children, as well as treatment of the Lennox Gastaut syndrome. CONCLUSIONS: The choice of AED depends upon seizure and/or syndrome type, patient age, concomitant medications, AED tolerability, safety, and efficacy. The results of this evidence-based assessment provide guidelines for the prescription of AEDs for patients with refractory epilepsy and identify those seizure types and syndromes where more evidence is necessary. SN - 1526-632X UR - https://www.unboundmedicine.com/medline/citation/15111660/Efficacy_and_tolerability_of_the_new_antiepileptic_drugs_II:_treatment_of_refractory_epilepsy:_report_of_the_Therapeutics_and_Technology_Assessment_Subcommittee_and_Quality_Standards_Subcommittee_of_the_American_Academy_of_Neurology_and_the_American_Epilepsy_Society_ L2 - http://www.neurology.org/cgi/pmidlookup?view=long&pmid=15111660 DB - PRIME DP - Unbound Medicine ER -